GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke MONDAY, Nov. 11, 2024 ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Weight-loss drugs, particularly newer options like GLP-1 receptor agonists, are revolutionising the treatment of obesity and ...

With the American Heart Association (AHA) and American Stroke Association (ASA) updating their guidelines for preventing ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

“Some patients may need a different medication altogether, like basal or prandial insulins or a sulfonylurea, during the ...

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.